Compare Citius Pharmaceuticals Inc (CTXR) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Kimberly Clark Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Kimberly Clark Corp trades at $97.72 (market cap $32.51B). The key difference: Kimberly Clark Corp is far larger — about 2386.9× Citius Pharmaceuticals Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Kimberly Clark Corp for 93 Days on average.
| CTXR | KMB | |
|---|---|---|
Market Cap | $13.62M | $32.51B |
Volume | 132,438 | 6,139,913 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $121.44 |
52-Week Low | $0.48 | $93.05 |
Typical Hold Time | 16 Days | 93 Days |
Enterprise Value | $3.79M | $38.07B |
Dividend Yield | — | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Kimberly-Clark (KMB) trades at $96.48, down 0.3% on the day, showing bearish technical signals with recent price weakness. The company maintains strong profitability with 11.79% net margins and 129.43% ROE, though revenue declined to $16.45B in 2025. Recent Q2 2026 earnings missed expectations, while analyst consensus remains cautiously optimistic with a $117.25 price target. Key developments include executive transitions and ongoing Kenvue acquisition negotiations with EU regulators.
KMB presents a mixed investment case with attractive 5.16% dividend yield and 54-year dividend growth streak, but faces execution risks from the Kenvue acquisition and cash flow pressures. The stock trades below analyst targets with bearish technical momentum, requiring careful monitoring of merger integration and cash flow sustainability for dividend investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
